Form 4: ABEONA THERAPEUTICS Director Sells Shares to Cover Tax Obligations

ABEONA THERAPEUTICS Director Faith L. Charles reported the sale of 10,738 shares of common stock on July 9, 2025, at a weighted average price of $5.8557 per share, primarily to cover tax obligations from restricted stock award vesting.

Summary

• Faith L. Charles, a Director of ABEONA THERAPEUTICS INC. (ABEO), reported a transaction involving the sale of common stock.
• The transaction date for the sale was July 9, 2025.
• A total of 10,738 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $5.8557 per share, with individual transaction prices ranging from $5.78 to $5.92.
• The primary purpose of this sale was to cover tax obligations associated with the vesting of restricted stock awards.
• Following this reported transaction, Faith L. Charles beneficially owns 139,094 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale of shares by a director was explicitly stated to cover tax obligations related to the vesting of restricted stock awards, a common and often pre-planned event for equity compensation. This does not inherently signal negative sentiment towards the company's future.

Positives

• The sale was explicitly stated to be for covering tax obligations related to the vesting of restricted stock awards, which is a common and often pre-planned event for equity compensation.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged sale not based on immediate, non-public insider information, which enhances transparency and compliance.

Negatives

• A director selling shares, even for tax purposes, can sometimes be perceived neutrally to slightly negatively by investors, though the stated reason mitigates significant concern.

Future Outlook

No specific future outlook or guidance for the company's performance or strategy is provided in this insider transaction report.

Management Comments

• "The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards."
• "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly for publicly traded companies where executives and directors receive equity compensation. It reflects standard compliance with SEC regulations for reporting changes in beneficial ownership.

Corporate Governance

Related Party Transactions

• The sale of common stock by Faith L. Charles, a Director of ABEONA THERAPEUTICS INC., constitutes a related-party transaction as it involves a key management personnel and the company's securities. This is a standard disclosure for insider trading activities.

Stakeholder Impact

• Shareholders: The sale slightly increases the public float of shares. Given the stated reason (tax obligations from vesting awards) and the Rule 10b5-1 plan, the impact on shareholder perception is likely neutral to slightly negative, as it does not suggest a lack of confidence in the company's future.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the issuer, any security holder, or the SEC staff.

Key Dates

Keywords

ABEONA THERAPEUTICS, ABEO, Form 4, insider trading, stock sale, director, equity compensation, restricted stock, tax obligations, 10b5-1 plan